ORIGINAL ARTICLE

Alternative splicing modifies the effect of mutations in COL11A1 and results in recessive type 2 Stickler syndrome with profound hearing loss

Allan J Richards,1,2 Gregory S Fincham,3 Annie McNinch,1,2,3 David Hill,2 Arabella V Poulson,3 Bruce Castle,4 Melissa M Lees,5 Anthony T Moore,6 John D Scott,3 Martin P Snaed3

ABSTRACT

Background Stickler syndromes types 1, 2 and 3 are usually dominant disorders caused by mutations in the genes COL2A1, COL11A1 and COL11A2 that encode the fibrillar collagens types II and XI present in cartilage and vitreous. Rare recessive forms of Stickler syndrome exist that are due to mutations in encoding type IX collagen (COL9A1 type 4 Stickler syndrome and COL9A2 type 5 Stickler syndrome). Recently, recessive mutations in the COL11A1 gene have been demonstrated to result in fibrochondrogenesis, a much more severe skeletal dysplasia, which is often lethal. Here we demonstrate that some mutations in COL11A1 are recessive, modified by alternative splicing and result in type 2 Stickler syndrome rather than fibrochondrogenesis.

Methods Patients referred to the national Stickler syndrome diagnostic service for England, UK were assessed clinically and subsequently sequenced for mutations in COL11A1. Additional in silico and functional studies to assess the effect of sequence variants on pre-mRNA processing and collagen structure were performed.

Results In three different families, heterozygous COL11A1 biallelic null, null/missense or silent/missense mutations, were found. They resulted in a recessive form of type 2 Stickler syndrome characterised by particularly profound hearing loss and are clinically distinct from the recessive types 4 and 5 variants of Stickler syndrome. One mutant allele in each family is capable of synthesising a normal α1(XI) procollagen molecule, via variable pre-mRNA processing.

Conclusion This new variant has important implications for molecular diagnosis and counselling families with type 2 Stickler syndrome.

INTRODUCTION

Type XI collagen along with type II collagen, forms the heterotypic fibrillar collagen fibrils found in cartilage and vitreous. It is a heterotrimer, encoded by three genes COL11A1 (MIM 120280), COL11A2 (MIM 120290) and COL2A1 (MIM 120140),1–7 the latter also encodes the homotrimer type II collagen that constitutes the major component of these collagen fibrils. Although type XI collagen is a quantitatively minor component of the fibrils it has an important role in regulating fibrillogenesis.8 Mutations of all three genes can result in different types of Stickler syndrome (MIM 108300, 604841, 184840),9–11 which is usually an autosomal dominant disorder with variable phenotype that includes myopia, retinal detachment, premature osteoarthritis, hearing loss, facial dysmorphism and midline clefting that can manifest as Pierre Robin sequence, or an isolated cleft palate.12 The COL11A2 gene is not expressed in the eye and mutations in that gene do not result in an eye phenotype.13 A recessive form of Stickler syndrome (MIM 614134, 614284)14–15 has been reported in association with null alleles of type IX collagen genes (COL9A1 MIM 120210 and COL9A2 MIM 120260). Type IX collagen connects heterotypic type II/XI collagen fibrils to other components of the extracellular matrix.16–17

A recent systematic review of published information on hearing loss in Stickler syndrome18 concluded that more than half of all patients have some form of hearing loss, but that this may vary between the different types. Hearing loss is usually mild to moderate, however when associated with COL11A1 and COL11A2 it is more common, more severe and presents at a younger age than for COL2A1. In the recessive forms, due to mutations in type IX collagen, the hearing loss is variable and has been described as mild to severe.14–15

The recessive disorder fibrochondrogenesis (MIM 228520), which is usually lethal, has also been shown to be due to mutations in COL11A1.19–22 In that disorder the mutations are either a combination of null alleles and missense mutations or biallelic null alleles. The carrier parents showed only mild clinical features such as myopia or hearing loss and were not considered to have Stickler syndrome.

COL11A1, COL11A2 and COL2A1 are all subject to alternative splicing,21–22 where inclusion or exclusion of exons encoding the N-propeptide region of the molecules results in isoforms that can vary in their interaction with other components of the extracellular matrix,23 and growth factors such as TGFβ1 and BMP-2.24 As previously demonstrated, mutations in the alternatively spliced exon 2 of COL2A1 result in a non-systemic (or predominantly ocular) form of type 1 Stickler syndrome25 (MIM 609508). Here we demonstrate that mutations, in two families, affecting the alternatively spliced exon 9 (also referred to as exon 8 or variable region 2)26,27 of COL11A1 which is not expressed in cartilage,28 are modified by the natural alternative splicing that occurs in this gene.
Both cases have a second mutation, but the combination of the two results in a recessive form of type 2 Stickler syndrome with profound hearing loss, rather than the more severe fibrochondrogenesis. In addition, we describe a third family with recessive type 2 Stickler syndrome that have a silent mutation which is variably spliced and able to express at least some normal $\alpha 1$(XII) collagen.

**MATERIALS AND METHODS**

Three families referred to the national Stickler syndrome diagnostic service for England were assessed clinically and with informed written consent, subsequently screened for mutations in COL11A1. The study was approved by the local research ethics committee.

**Gene analysis**

The COL11A1 gene was analysed by amplification and sequencing of all exons as previously described.\(^{29}\) In addition, possible regions of gene deletion/duplication were examined by multiplex ligation-dependent probe amplification using commercially available probes (MRC-Holland, Amsterdam, the Netherlands). The cDNA numbering is derived from the COL11A1 transcript NM_001854.3. The exons are numbered 1–68 as described in the reference sequences (NM_001854.3, NM_008069.2 and NM_008069.3), where exons 6, 7 and 9 are alternatively spliced, rather than numbered as exons 1–67 as in Annunen et al.\(^{27}\) Transcript NM_001854.3 contains exons 6 and 9 (also referred to as exon 6A and 8, respectively) but not exon 7 (also referred to as exon 6B).

**Mutation analysis**

The effect of sequence variants on pre-mRNA processing was assessed in silico and functionally. Functional studies were performed using either minigenes as splicing reporters or cultured cells obtained from a heterozygous carrier. The minigene system USR13\(^{30}\) consisted of a cassette of four exons (43–46) from the COL2A1 gene into which a test exon could be inserted to obtain normal and variant hybrid minigene constructs. These could then be expressed in cultured mammalian cells. Cultured dermal fibroblasts obtained from patients were incubated with and without emetine, an inhibitor of nonsense mediated decay (NMD). RNA prepared from either transfected or patients’ cells was analysed by reverse transcription PCR (RT-PCR) as previously described.\(^{30}\)

Sequence variations were analysed in silico, using Alamut V2.0 (Interactive Biosoftware, Rouen, France), a software package that uses four different programmes to predict the effect of variants on pre-mRNA splicing (as previously described)\(^{30}\) and three programmes to analyse the effect of amino acid changes on protein function. These are PolyPhen-2, sorting intolerant from tolerant (SIFT) and align Grantham variation Grantham deviation (GVGD), which are also freely available as separate stand-alone utilities, (http://genetics.bwh.harvard.edu/pph2/, http://sift.jcvi.org/ , http://ggvd.iarc.fr/).

**Quantitative RT-PCR**

RNA isolated from cultured cells of the carrier for the c.2607A>G, p.Ala869Ala was reverse transcribed with a gene specific primer and superscript II (Invitrogen, http://www.invitrogen.com). The relative amount of the G allele was compared with the expression of the A allele by quantitative PCR using primers located in exon 32 and 33 and fluorescently labelled cDNA probes specific for each allele. RNA from a normal individual was used as a positive control for the A allele and a negative control for the G allele. Each reaction was performed in triplicate and this was repeated three times.

A chromo4 machine (BioRad, http://www.bio-rad.com) was used to measure the amount of fluorescence produced from each amplification reaction, and the Opticon-Monitor software (BioRad, http://www.bio-rad.com) was used to measure the relative difference in expression between the normal A and mutant G allele.

**RESULTS**

In each family, two unique mutations/variants were found as illustrated in figure 1 and online supplementary figure S1.

**Family 1**

The proband had been born with a cleft palate and subsequently found to be profoundly deaf with no recordable response from the left ear up to 100 dB and only a barely recordable response at 250 Hz/100 dB for the right ear. She communicates as an adult with sign language. Despite being hypermetropic (+3.50DS right, +4.50DS left) ophthalmological assessment revealed a hypoplastic vitreous gel architecture,\(^{29}\) without the membranous or beaded congenital vitreous anomaly. Assessment of her parents revealed insignificant, age-compatible sensorineural hearing loss for her mother (25 dB/4000 Hz) and mild to moderate sensorineural hearing loss in her father (40 dB/1000–4000 Hz). Both parents had unremarkable vitreous architecture, exhibiting only mild age related vitreous syneresis. The pedigree is illustrated in figure 1.

Mutations in exon 9 (c.1191delT, p.Asn398Metfs*19) and exon 58 (c.4259G>T, p.Gly1420Val) were found in the proband. Analysis of the parents’ DNA showed that the proband had inherited one mutation from each parent. The c.1191delT mutation has been previously reported, but erroneously located in exon 6 instead of exon 9.\(^{31}\) Because skipping of exon 9 would leave the message inframe and a functional collagen expressed, studies using RNA obtained from cultured

![Figure 1](http://www.jmg.bmj.com/)

**Figure 1** Inheritance patterns of mutations. The pedigrees indicate the inheritance of each mutation in three different families. Solid squares/circles indicate individuals with type 2 Stickler syndrome. Vertical bars are carriers that had minor clinical signs associated with Stickler syndrome or a normal clinical appearance.
dermal fibroblasts with the exon 9 mutation (c.1191delT) were used to assess whether any nonsense associated exon skipping resulted from this mutation. Cultured dermal fibroblasts which constitutively express the alternatively spliced exon 9 were treated with a nonsense mediated decay inhibitor. Amplification of cDNA (figure 2A), showed that the uninhibited cells produced a homozygous cDNA sequence which included exon 9, and since nonsense associated exon skipping would have resulted in a heterozygous sequence, this demonstrated that only the normal allele was expressed. Cells treated with the NMD inhibitor expressed both alleles, thereby confirming that the mutant allele would normally be naturally degraded by this cellular RNA quality surveillance system. However in tissues not expressing exon 9 the mutation would be naturally removed from the mature transcript. The p.Gly1420Val mutation disrupted the Gly-Xaa-Yaa amino acid repeat sequence of the collagen molecule, which is typical of pathogenic mutations in collagen molecules, and was predicted to be pathogenic by all three protein analysis tools in Alamut.

Family 2

Two young boys, with severe and profound hearing loss, presented with parents who exhibited only mild clinical signs associated with Stickler syndrome, but were not considered to have the disorder. The proband was referred at age 20 months having been born with congenital high myopia (−7DS bilaterally), Pierre Robin sequence and profound hearing loss (90 dB), for which he had been treated with bilateral cochlear implants. His newborn brother (18 days old) also had Pierre Robin sequence and auditory brainstem assessment demonstrated no recordable responses at over 95 dB; typanometry was normal. Audiometry findings were confirmed on retesting and cochlear implants are planned. Their father had a high arched palate and mild, asymptomatic high tone hearing loss. The mother exhibited mild, asymptomatic hearing loss (35 dB/1000–2000 Hz); she also reported a history of hearing loss in her family. She had healthy compact vitreous gel architecture. The pedigree is illustrated in figure 1. Analysis of COL11A1 identified a frameshift mutation c.1421dupC, p.Gly475Argfs*9 in exon 13 and a sequence variant c.991-24A>G in intron 8 which was absent from the dbSNP (single nucleotide polymorphism) variation database (http://www.ncbi.nlm.nih.gov/snp). In silico analysis of this variant predicted that it created an alternative exon 9 acceptor splice site. It was also analysed functionally using minigenes, by cloning the normal and variant alleles into the splicing reporter USR13. This vector has been successfully used to assess other non-AG-GT splice site mutations that result in exon skipping

Figure 2. Analysis of exon 9 mutations c.1191delT and c.991-24A>G by RT-PCR. RNA from a cell line heterozygous for the c.1191delT mutation was analysed by RT-PCR and sequenced (A). cDNA from cells incubated with emetine to inhibit NMD (+NMD) had the frameshift mutation, whereas cDNA from uninhibited cells (+NMD) had a homozygous sequence from the normal allele only. COL11A1 exon 9, including 682 bp of surrounding intron sequence, was amplified from genomic DNA containing the c.991-24A>G mutation (B). This was cloned into the splicing reporter USR13, between COL2A1 exons 44 and 45. Normal and mutant alleles were expressed in MIO-M1 cells, with the resulting RNA analysed by RT-PCR and sequencing (B). The variant cDNA had an additional 23 bp, which corresponded to the sequence from COL11A1 IVS8 and a de novo acceptor splice site created by the mutation. Green=A, red=T, blue=C, black=G.

Because exon 9 is not expressed in all tissues (NM_080630.3, transcript variant C) this mutation, like the c.1191delT mutation, would be naturally removed from transcripts in those tissues and have no effect.
Family 3

The proband was a young girl (figure 3), born prematurely at 32 weeks and tube fed for 4 weeks, but without any evidence of a cleft palate. Hearing loss was diagnosed at 5 weeks of age, later being confirmed with pure tone audiometry which showed severe mixed conductive and sensorineural hearing loss from 250 Hz–8000 Hz with flat tympanometry. At 2 years of age concerns about visual development and a very pale fundal reflex led to referral for investigation of a possible retinal dystrophy. Refraction under cycloplegia revealed high myopia (−12.50DS right, −12.50DS left) and slit-lamp examination noted the type 2 beaded vitreous anomaly, associated with mutations in COL11A1.29 Despite the high refractive error, the discs were of normal size and configuration. A clinical diagnosis of probable type 2 Stickler syndrome was made. Full field electroretinogram, pattern reversal visual evoke potential and flash visual evoke potential were normal. Both parents exhibited healthy compact vitreous gel architecture and no evidence of hearing loss on audiometry testing. The proband exhibited clinical joint laxity, but with no evidence of dysplastic changes of the hips or pelvis visible on radiology. Analysis of COL11A1 identified a silent variant c.2607A>G, p.Ala869Ala and a missense alteration c.5398G>T, p.Gly1800Cys. Both of these changes are novel and were absent from the dbSNP variation database (http://www.ncbi.nlm.nih.gov/snp). Analysis of the parents’ DNA showed that the silent variant was inherited from the father and the missense change from the mother. Analysis in silico predicted that the silent DNA variant created a donor splice site within exon 33 and also a potential binding site for the splicing factor SRp55. Using RNA obtained from the father’s cultured dermal fibroblasts, RT-PCR demonstrated three splice isoforms (figure 4). First, RNA from cells uninhibited for NMD had the normal and variant sequence, demonstrating that the variant allele could be spliced normally, although there appeared to be unequal peak heights in the sequence chromatogram (figure 4). Using RNA from cells where NMD was inhibited, the use of the variant sequence as a donor splice site was observed by sequencing in the reverse direction.

![Figure 3](image-url) Facial photographs of a child with recessive type 2 Stickler syndrome. The child has c.2607A>G, p.Ala869Ala and c.5398G>T, p.Gly1800Cys mutations in COL11A1. The p.Gly1800Cys was inherited from her mother who is also shown.

![Figure 4](image-url) RT-PCR analysis of the c.2607A>G, p.Ala869Ala mutation. Cultured cells from a heterozygous carrier were incubated with (−NMD) or without (+NMD) emetine to inhibit nonsense mediated decay. NMD was also inhibited in a normal cell line as a control. RNA was analysed by RT-PCR and sequenced in the forward (A) and reverse (B) directions. Text sequence represents the sequence seen in uninhibited cells (upper) and the additional sequence obtained from inhibited cells (lower). In (A) an additional sequence was located between exons 32 and 33 (in bold type), which corresponded to a pseudoexon in intron 32. In the reverse direction, the mutant sequence (arrowed) was present in cDNA from uninhibited (+NMD) cells. When nonsense mediated decay was inhibited an additional transcript was seen which corresponded to the use of the GTGCAC sequence (in bold) as a donor splice site.
direction, confirming the in silico prediction. In addition to the variant creating a donor splice site in the exon, sequencing in the forward direction also identified insertion of 16 nucleotides between exons 32 and 33. An examination of intron 32 showed that the inserted sequence was present at c.2557−186 to −171, it was preceded by a cag sequence and followed by the sequence gaag, which matched consensus acceptor and donor splice sites, respectively. Therefore the inserted sequence represented a pseudoexon which was activated by the c.2607A>G variant. Both of the misspliced transcripts resulted in frameshifts and premature termination of translation, reducing the level of expression from the mutant G allele. Quantitative RT-PCR indicated that the expression of the G allele was approximately 42 ± 3.5% of the normal A allele (data not shown), meaning that the misspliced transcripts represented around 58% of transcripts from the G allele.

The missense change inherited from the mother changed a conserved glycine to cysteine in the C-propeptide region of the molecule (figure 5). Disruption to the pattern of cysteines in the C-propeptide of collagen molecules has been found in various other collagenopathies32 and in silico analysis predicted that the amino acid change was damaging.

**DISCUSSION**

Stickler syndrome is usually a dominant disorder due to mutations in the collagen genes COL2A1, COL11A1 and COL11A2. Although there are rare recessive forms, these have all been reported in consanguineous families where the mutations have been homozygous14 15 31 33 Here we report three non-consanguineous families with a novel recessive form of type 2 Stickler syndrome, without consanguinity to assist interpretation of the nature of exons in collagen genes, which typically encode a complete set of Gly-Xaa-Yaa amino acid repeat sequences, such mutations result in shortened α(XI) procollagens that contain the region encoded by exon 9 in rat long bones is similar −28 and that only transcripts expressed this exon (NM_001854.3, NM_080692.2 transcript variants A and B) will be affected. Whereas transcript variant C (NM_080693.3) expressed in cartilage will not be altered. The examples of recessive Stickler syndrome that we describe here demonstrate that their premise is likely to be incorrect, and that the recessive Stickler syndrome phenotype is more probably due to the ability to synthesise normal α(XI) collagen molecules because the mutations are removed by naturally occurring alternative splicing.

The expression of COL11A1 exon 9 in rat long bones is similar to the expression of the long form of type II collagen, that contains the region encoded by exon 2 of COL2A1.44 Both are present in immature chondrocytes but disappear as these cartilage precursors differentiate and mature. This would explain why the resulting phenotype in these individuals presented as Stickler syndrome rather than fibrochondrogenesis. As with the mechanism

Further phenotypes associated with mutations in COL11A1 are Marshall syndrome and fibrochondrogenesis. Marshall syndrome is a differential diagnosis to type 2 Stickler syndrome, it results mainly from exon skipping mutations of COL11A1 and differs in the severity of facial features that may be present.27 Fibrochondrogenesis was first characterised molecularly by Tompson et al,19 who found heterozygous null alleles inherited along with a substitution of an obligate glycine on the second allele. Later Akawi et al26 characterised two families who both had biallelic null mutations. Here we have demonstrated how, due to alternative splicing, which can be either natural or pathogenic in origin, similar null/missense or biallelic null mutations result in Stickler syndrome rather than fibrochondrogenesis (table 1).

**Exon 9/intron 8 mutations**

The c.1191delT mutation seen in family 1 has been previously reported in a homozygous state,13 emphasising the recessive nature of this mutation. However, Alzahrani et al31 erroneously located the mutation in exon 6. As in family 1 the patient described by Alzahrani et al13 had hearing loss, cleft palate but not myopia, although vitreoretinal degeneration was present in both. Alzahrani et al suggested that the resulting Stickler phenotype questioned whether fibrochondrogenesis was simply a case of COL11A1 deficiency, and failed to consider that in fact exon 9 is naturally alternatively spliced25–28 and that only transcripts expressing this exon (NM_001854.3, NM_080692.2 transcript variants A and B) will be affected. Whereas transcript variant C (NM_080693.3) expressed in cartilage will not be altered. The examples of recessive Stickler syndrome that we describe here demonstrate that their premise is likely to be incorrect, and that the recessive Stickler syndrome phenotype is more probably due to the ability to synthesise normal α(XI) collagen molecules because the mutations are removed by naturally occurring alternative splicing.

The expression of COL11A1 exon 9 in rat long bones is similar to the expression of the long form of type II collagen, that contains the region encoded by exon 2 of COL2A1.44 Both are present in immature chondrocytes but disappear as these cartilage precursors differentiate and mature. This would explain why the resulting phenotype in these individuals presented as Stickler syndrome rather than fibrochondrogenesis. As with the mechanism
that removes mutations in exon 2 from COL2A1 and results in a non-systemic form of Stickler syndrome, so the natural alternative splicing of COL11A1 exon 9 modifies the effect of the mutations, consequently the severity of abnormal skeletal development is reduced. However, this exon is expressed in Meckel's cartilage, which gives rise to the malleus and incus of the inner ear, in addition to the anterior ligament of the malleus tympanic plate, which is likely to explain why there is a more severe hearing than skeletal phenotype in these patients.

Like the c.1191delIT mutation the c.991-24A>G mutation in intron 8, seen in family 2, will only affect tissues that express exon 9. Although not obviously pathogenic a combination of functional minigenine analysis, in silico analysis, absence from the variation sequence databases and inheritance patterns, together indicate the pathogenic nature of this mutation. The family with the c.991-24A>G mutation also had a frameshift c.1421dupC mutation, predicted to result in two null alleles, similar to the families described by Akawi et al., except that here one (c.991-24A>G) is modified by alternative splicing of exon 9, whereas those causing fibrochondrogenesis affect constitutive exons.

**Glycine substitution**

As with the cases of fibrochondrogenesis described by Thompson et al., one patient characterised here possesses similar null/mis-sense mutations, but has Stickler syndrome instead. The missense mutation p.Gly1420Val was coinherited with a null allele due to a mutation (c.1191delIT) in the alternatively spliced exon 9. The missense mutation was also present in the patient’s mother who exhibited only age-related hearing loss and no other clinical signs usually associated with mutations of COL11A1. This may be surprising, however, in other collagenous ligation the substitution of obligate glycines can result in a wide range of phenotypic severity from lethal to mild, with the genes for type I collagen and osteogenesis imperfecta being the most studied. To date only eleven glycine substitutions have been described in COL11A1, and so the range of possible resulting phenotypic variation is currently unknown and difficult to predict from any particular missense mutation. The heterozygous carriers of similar glycine substitutions described by Tompson et al. were also not considered to have Stickler syndrome and presented with only mild phenotypes, such as myopia or hearing loss. It would therefore appear that as with the quantitatively major collagens such as type I and type II collagen, substitutions of an obligate glycine in α1(XI) collagen can result in a spectrum of phenotypes, some resulting in Stickler syndrome, while others may produce only subtle clinical features not recognised as that disorder. The report of recessive Marshall syndrome, in a consanguineous family with a homozygous glycine substitution in α1(XI) collagen supports this conclusion. In heterozygous cases of recessive type 2 Stickler syndrome there is a risk that a glycine substitution may be mistaken for dominant mutation, and the recessive nature of the change overlooked.

**Silent mutation**

As has previously been seen in COL2A1 and type 1 Stickler syndrome, here a silent mutation in COL11A1 results in missplicing of the COL11A1 transcript. The silent c.2607A>G, p.Ala869Ala mutation in family 3 resulted in three different splice isoforms. First it was spliced normally, second the mutation created a de novo donor splice site (as predicted by in silico analysis) and third it also activated a pseudogene in the preceding intron. Both of the misspliced isoforms resulted in premature termination of the message and were only detected after inhibition of nonsense mediated decay. The effect of this mutation is to reduce the level of expression of the mutant allele, without resulting in a null allele. Unlike in families 1 and 2, where naturally occurring alternative splicing removes the mutation from certain tissues, here it was variation caused by the mutation that modified the phenotype. It is possible that the proportion of the various isoforms may differ from tissue to tissue, depending upon the expression of transacting splicing factors, but this has not been investigated.

**C-propeptide mutation**

Family 3 also had a novel C-propeptide mutation, changing a conserved glycine residue and incorporating an extra cysteine into the C-propeptide. This domain of the fibrillar collagens has a highly conserved pattern of cysteine residues which are important in forming intramolecular and intermolecular disulphide bonds during the trimerisation process of a collagen molecule. Although mutations in the C-propeptide of other fibrillar collagens have been described, this is the first example of a C-propeptide mutation in α1(XI) collagen. In other collagens, mutations within this domain can produce a wide variety of phenotypes depending upon how they affect its folding and function. It is likely that this extra cysteine will disrupt this process, as do similar mutations, that also create additional cysteines in the C-propeptides of α1(I) and α1(II) collagens. Along with the silent mutation c.2607A>G, p.Ala869Ala, inherited from the father, they result in Stickler syndrome. Because the silent mutation can also be spliced normally, it is not clear what phenotype would result if this novel C-propeptide mutation had been inherited with a null allele.

In summary, the identification here of a recessive form of type 2 Stickler syndrome, associated with unusually profound hearing loss, highlights the necessity for a detailed examination of both parents and a detailed gene analysis. It should not be assumed that a glycine substitution in the α1(XI) collagen helix is dominant and the sole pathogenic cause of type 2 Stickler syndrome. Of the 77 type 2 Stickler patients, with characterised dominant mutations seen in our clinic, none had profound (ie, greater than 95 dB) hearing loss (unpublished data), which agrees with the recent review by Acke et al. In this respect, families 1 and 2 were distinctive in their profound hearing loss, which may be an indication that it is associated with a recessive mode of inheritance.

**Acknowledgements** We would like to thank the technical and scientific staff in the Regional Molecular Genetics Laboratory, Cambridge UK, for their assistance with the genetic analysis. We would also like to thank AGNIS (http://www.specialisedservices.nhs.uk).

**Contributors** The patients were examined clinically and detailed family histories obtained by GSF, AM, BC, MML, ATM, A VP, and MPS. RNA studies were designed by AJR and performed by AJR and DH. In silico analysis was performed by AJR. The manuscript was written by AJR JDS and MPS, proof-read and edited by the other authors.

**Competing interests** None.

**Patient consent** Obtained.

**Ethics approval** Cambridge Research Ethics Committee.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Web resources**

- Online Mendelian Inheritance in Man (OMIM) http://www.omim.org

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
Supplementary Figure 1. COL11A1 mutation sequences.

Variants found when sequencing individuals with Stickler syndrome. Green = A, Red = T, Blue = C, Black = G. The cDNA numbering uses the reference sequence NM_001854.3. where c.1 refers to the A of the initiating ATG codon for methionine which is numbered as p.1Met.

Supplementary Figure 2. Minigene analysis of COL11A1 mutations.

Both mutant (M) and normal (N) COL11A1 exon 9 alleles from an individual with the c.991-24A>G mutation were cloned into the splicing reporter USR13, transfected into MIO-M1 cells and analysed by RT-PCR and agarose gel electrophoresis using either vector specific primers (A) or a vector specific primer and a COL11A1 exon 9 specific primer (B). Other mutations C-G (as indicated) from individuals with dominant type 2 Stickler syndrome were analysed in the same splicing reporter. Products representing exon skipped transcripts are indicated with arrows. An asterisk (*) indicates the product from the c.991-24A>G construct which is larger than the normal control. 100 bp size standards (S) are included for each reaction and the 500 bp standard indicated.
Supplementary Figure 2